Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. Frost N, et al. Among authors: alt j. Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613692 Free PMC article.
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M. Stratmann JA, et al. Among authors: alt j. J Cancer Res Clin Oncol. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22. J Cancer Res Clin Oncol. 2018. PMID: 30244389
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F, Basara N, Schütte W, Späth-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, Griesinger F, Christoph DC. Krefting F, et al. Among authors: alt j. Oncol Res Treat. 2019;42(5):243-255. doi: 10.1159/000499321. Epub 2019 Apr 17. Oncol Res Treat. 2019. PMID: 30995666
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC. Faehling M, et al. Among authors: alt j. Lung Cancer. 2020 Dec;150:114-122. doi: 10.1016/j.lungcan.2020.10.006. Epub 2020 Oct 21. Lung Cancer. 2020. PMID: 33126091
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Büttner R, Heukamp LC, Stenzinger A, Jänicke M, Fleitz A, Zacharias S, Dille S, Hipper A, Sandberg M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Thomas M, Griesinger F; CRISP Registry Group. Sebastian M, et al. Among authors: alt j. Lung Cancer. 2021 Apr;154:51-61. doi: 10.1016/j.lungcan.2021.02.005. Epub 2021 Feb 13. Lung Cancer. 2021. PMID: 33611226 Free article.
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
Saalfeld FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, Reissig TM, Laßmann S, Thiel S, Stratmann JA, Marienfeld R, Berger J, Desuki A, Velthaus JL, Kauffmann-Guerrero D, Stenzinger A, Michels S, Herold T, Kramer M, Herold S, Tufman A, Loges S, Alt J, Joosten M, Schmidtke-Schrezenmeier G, Sebastian M, Stephan-Falkenau S, Waller CF, Wiesweg M, Wolf J, Thomas M, Aust DE, Wermke M; National Network Genomic Medicine Lung Cancer (nNGM). Saalfeld FC, et al. Among authors: alt j. J Thorac Oncol. 2021 Nov;16(11):1952-1958. doi: 10.1016/j.jtho.2021.06.025. Epub 2021 Jul 8. J Thorac Oncol. 2021. PMID: 34245914 Free article.
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S; National Network Genomic Medicine Lung Cancer (nNGM). Janning M, et al. Among authors: alt j. Ann Oncol. 2022 Jun;33(6):602-615. doi: 10.1016/j.annonc.2022.02.225. Epub 2022 Mar 6. Ann Oncol. 2022. PMID: 35263633 Free article.
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis.
Stratmann JA, Timalsina R, Atmaca A, Rosery V, Frost N, Alt J, Waller CF, Reinmuth N, Rohde G, Saalfeld FC, von Rose AB, Acker F, Aspacher L, Möller M, Sebastian M. Stratmann JA, et al. Among authors: alt j. Ther Adv Med Oncol. 2022 Jun 4;14:17588359221097191. doi: 10.1177/17588359221097191. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677321 Free PMC article.
398 results